Humacyte, Inc. (HUMAW)
The price, the headline numbers and the latest news, in one place.
Humacyte, Inc. (HUMAW) Stock Price, Analysis & Data
No data available
| Bid | 0 |
| Market Cap | n/a |
| Revenue (ttm) | 2.12M |
| Net Income (ttm) | -96.7M |
| 2.47 | |
| -3.16 | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.01 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 0.2 |
| Volume | 258,659 |
| Avg. Volume (20D) | n/a |
| Open | 0.23 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 0.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HUMAW
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign...
Financial Performance
In 2025, Humacyte's revenue was 2.04M, an increase of undefined% compared to the previous year's 0. Earnings were -40.83M, a decrease of -72.54%.
Financial StatementsEarnings Surprise
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
3 weeks ago · Simply Wall St.
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In WomenHumacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients. The company plans to file a supplementa...